End of the Universe Coming Sooner Than Thought, Scientists Reveal
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
The end of everything is coming sooner than we thought—but don't worry, you've probably still got time to work through your bucket list.
This is the conclusion of researchers from Radboud University in the Netherlands, who calculated how long it would take for the last remnants of the stars to decay into oblivion.
The universe, they say, will go absolutely dark in 1078 years (that's a 1 with 78 zeros)—far sooner than the previous estimate of 101100 years (or 1 with 1100 zeros).
The process behind this disintegration is related to so-called Hawking radiation, the theoretical process by which black holes are thought capable of evaporating to nothing.
"By asking these kinds of questions and looking at extreme cases, we want to better understand the theory—and perhaps one day, we unravel the mystery of Hawking radiation," said paper author and mathematics professor Walter van Suijlekom.
An artist's impression of a neutron star evaporating via Hawking-like radiation.
An artist's impression of a neutron star evaporating via Hawking-like radiation.
Daniëlle Futselaar/artsource.nl
In 1975, the British theoretical physicist professor Stephen Hawking argued that—despite their reputation for being inescapable—it is possible for material to leave a black hole.
This process relies on a weird quantum phenomenon. Hawking proposed that pairs of subatomic particles and their antiparticle opposites are able to pop into existence as a result of fluctuations in the background "vacuum energy" of space.
In almost all situations, these particles would annihilate and there would be no lasting effect. However, Hawking argued, when such pairs appear on the event horizon of a black hole, it would be possible for one with negative energy to fall in and the other to get away.
To an observer, it would appear that the black hole was emitting radiation—and gradually losing mass and rotational energy in the process. Given this, black holes that aren't actively gobbling up material gradually shrink at a rate that is inversely proportional to its mass.
The new paper builds on a 2023 study in which van Suijlekom and his colleagues—physicists Heino Falcke and Michael Wondrak—showed that all objects with a gravitational field should also be able to evaporate via a process similar to Hawking radiation.
The team determined that the evaporation time of a given object is dependent only on its density—and were surprised to discover that the average neutron star and stellar black hole take about the same amount of time to decay: 1067 years.
This was a surprise; black holes have a far stronger gravitational field, and so were expected to evaporate faster.
However, Wondrak explains, "Black holes have no surface. They reabsorb some of their own radiation, which inhibits the process."
Do you have a tip on a science story that Newsweek should be covering? Do you have a question about the end of everything? Let us know via science@newsweek.com.
References
Wondrak, M. F., van Suijlekom, W. D., & Falcke, H. (2023). Gravitational Pair Production and Black Hole Evaporation. Physical Review Letters, 130(22). https://doi.org/10.1103/PhysRevLett.130.221502
Falcke, H., Wondrak, M. F., & van Suijlekom, W. D. (2025). An upper limit to the lifetime of stellar remnants from gravitational pair production. Journal of Cosmology and Astroparticle Physics. https://doi.org/10.1088/1475-7516/2025/05/023
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
6 hours ago
- Los Angeles Times
Escape from reality with ‘The Librarians: The Next Chapter' this weekend
Welcome to Screen Gab the newsletter for everyone who needs a break from doomscrolling. If your brain needs a fantasy adventure to escape the realities of life, perhaps the escapades of a time-traveling librarian will suit your needs. 'The Librarians,' which started as a trio of TV movies that evolved into a four-season TV series, has built out its universe with the recent spinoff 'The Librarians: The Next Chapter.' Showrunner Dean Devlin stopped by Guest Spot to discuss how the new show connects to the wider franchise. And if you're into crime dramas as a form of escapist TV, this week's streaming recommendations include a new British detective drama that features a mismatched crime-solving duo and the prequel series in 'Dexter's' expanding serial killer universe. Must-read stories you might have missed 50 years after Marshal Matt Dillon's last draw, 'Gunsmoke' is a streaming hit: The adult western drama with James Arness is finding loyal fans and new audiences on Peacock, Paramount+ and Pluto TV. Commentary: Why on earth is Dr. Phil involved in immigration raids? Another made-for-TV event from a reality star president: Of all the alarming things that have happened in L.A., Dr. Phil hanging out with Trump's top border policy advisor during immigration raids was the weirdest. In 'Murderbot,' an anxious scientist and an autonomous robot develop a workplace-trauma bond: Alexander Skarsgård and Noma Dumezweni, co-stars of Apple TV+'s 'Murderbot,' discuss Episode 6 of the sci-fi series and the autism-coded robot at the center of the show. 'Materialists' is a smart and funny all-star love triangle with its own commitment issues: In Celine Song's rom-com follow-up to her Oscar-nominated 'Past Lives,' Pedro Pascal is rich, Chris Evans is poor and Dakota Johnson is a matchmaking mercenary. Recommendations from the film and TV experts at The Times 'Death Valley' (BritBox) Set not in our own dry desert but the verdant valleys of Wales, this adorable and comical mystery series from the great Timothy Spall, OBE — longtime favorite of director Mike Leigh and familiar to many as Peter Pettigrew in five 'Harry Potter' movies — stars as John Chapel, a former TV police detective living in small-town isolation after the death of his Welsh wife. Along comes Gwyneth Keyworth as the world's sweetest (actual) police detective Janie Mallowan, Chapel's biggest fan who knocks on his door in the middle of an investigation. After some back-and-forth, push and pull, they become one of those pro-am teams that figure in so many detective shows — like 'Castle,' without the sex — and never better done than here. Chapel takes to the job in grand thespian style, playing characters, improvising and analyzing motives through character analysis. (He's not always right.) Janie is alternately stressed and impressed. Backdrops for the cases include a local theater production, a walking group, a wedding and a school reunion — cozy stuff. — Robert Lloyd 'Dexter: Original Sin' (Paramount+ with Showtime) If superheroes can have origin stories, why not serial killers carrying on their secret mission of justice? That's the concept of Showtime's 'Dexter: Original Sin,' which travels back to 1991 to show how the crafty Dexter Morgan, the forensics specialist who moonlighted as a vigilante, began his killing ways while working as an intern at the Miami Metro Police Department. The series premiered last year as a prequel spinoff of 'Dexter,' the popular drama/dark comedy that ran for eight seasons and later continued its story in the sequel series 'Dexter: New Blood.' Patrick Gibson uncannily captures the mannerisms, facial expressions and inflections of 'Dexter' star Michael C. Hall, who provides the trademark narration that was one of the signatures of the original series. The show is the perfect appetizer for the July 11 premiere of 'Dexter: Resurrection,' which brings the titular antihero back to life despite being 'shot to death' by his son Harrison (Jack Alcott) in the finale of 'Dexter: New Blood.' — Greg Braxton A weekly chat with actors, writers, directors and more about what they're working on — and what they're watching 'The Librarians' is back after more than seven years, but things are a little different from when we last visited this fantasy land, which spanned three films (starring Noah Wyle) and a four-season TV series. In its latest iteration, 'The Librarians: The Next Chapter,' we're introduced to a new librarian named Vikram Chamberlain (Callum McGowan), who time-traveled from 1847 and now finds himself stuck in the present. He returns to his castle in Belgrade, Serbia only to find that it's now a museum — but more notably, his arrival releases magic across the continent, leading to some strange occurrences. He has to clean up the mess, with some help in the form of guardian Charlie (Jessica Green), scientist Lysa (Olivia Morris) — who inherited the castle — and historian Connor (Bluey Robinson). For fans of the original series, Christian Kane makes a guest appearance as librarian Jacob Stone. Also returning is showrunner and executive producer Dean Devlin, who is carrying the torch on the series. He stopped by Screen Gab to talk about the new season, which currently airs on TNT and is also available for streaming on TNT's website and app, — Maira Garcia 'The Librarians' has amassed a legion of loyal fans over the years, first with the films and then with the series. What made you decide to return to it and how did you approach developing 'The Next Chapter' with a new cast? Honestly, I never wanted to stop telling stories in the world of the magical Library! When an opportunity came up to continue the franchise, I jumped at it. I didn't want to reboot the story, because in my mind (and the fans) the original team of Librarians are still out there doing missions. I wanted to focus on a different story that takes place in parallel. When the idea of a Librarian from the past appearing today, it felt like just the right 'fish out of water' story we needed to kick off a new series. The series features this push and pull of logic and magic, history and fantasy. How do you juggle history with the supernatural elements of the show? It's really important to us that viewers can Google things we talk about in our show. While we may not follow exactly the legends in the zeitgeist, we wanted there to be enough of a connection to deepen the enjoyment of our adventures. So history and mythology are at the heart of our show. Sometimes we'll give an alternate perspective or backstory, but there is always a nugget [of] connection to the stories we want to tell. Throughout your career, you've worked on a number of sci-fi and fantasy films and series like 'Stargate,' 'Independence Day' and 'The Ark.' What is it about these genres that appeals to you, and why do you think audiences gravitate toward them? Often 'escapist' entertainment is looked down upon as a lesser art form. But I find that audiences, especially after dealing with things like a pandemic, economic and personal hardships, [or] political divisions, have a real NEED to escape into a world of optimism and wonder and adventure. I'm no exception. What have you watched recently that you're recommending to everyone you know? It's not super recent, but I've loved watching 'Only Murders in the Building' [Hulu], 'Ted Lasso' [AppleTV+], 'Star Trek: Strange New Worlds,' 'Star Trek: Picard' (especially season 3) [both on Paramount+] and the new 'Doctor Who' [Disney+]. What's your go-to comfort watch, the film or TV show you return to again and again? If 'Tombstone' or 'Enter the Dragon' is playing on late-night TV, then I'm not getting any sleep. And of course, the 10th and 11th Doctors on 'Doctor Who' are a constant fallback watch for me.
Yahoo
7 hours ago
- Yahoo
‘Transformative': the UK lab working on a way to halt genetic type of dementia
Behind the gleaming glass facade of an office block in east London's Docklands, Dr Martina Esposito Soccoio is pipetting ribonucleic acid into test tubes. Here, not far from Canary Wharf's multinational banks, a British university spinout is working on a breakthrough treatment for a form of dementia that affects millions of people worldwide. There is no cure for dementia at present, but scientists at AviadoBio hope their clinical studies can stop the progression of a particular genetic type of frontotemporal dementia (FTD). 'It may be one of the first dementias to have a definitive treatment, a cure if you like, a really transformative treatment that allows people to live much longer and much more normal lives,' says Prof James Rowe, a consultant neurologist at Cambridge's Addenbrooke's hospital who is involved in the UK trial. FTD mainly affects the front and sides of the brain and, unlike Alzheimer's disease, does not begin with memory loss, which tends to occur later. It is characterised by progressive loss of language and changes in personality and behaviour. Most cases are diagnosed in people aged 45 to 65, but it can affect those in their 20s and 30s. There are an estimated 20,000 to 40,000 people living with FTD in the UK, and between 1 million and 2 million in the world. Rowe says: 'It's a double-edged sword: the young onset, the high genetic burden and rapid illness are also features that perhaps make it more tractable to treat.' The Die Hard and Pulp Fiction actor Bruce Willis, who recently celebrated his 70th birthday, was diagnosed two years ago with FTD, which his family described as a 'cruel disease'. They have not said whether he has a genetic form of FTD. The gene therapy developed by AviadoBio, which was spun out of Prof Christopher Shaw's research lab at King's College London in 2021, targets a type of FTD known as FTD-GRN. This is caused by mutations of a gene that lead to a deficiency of progranulin (GRN), a protein that is essential for maintaining healthy brain cells. AviadoBio, which employs 60 people, signed an exclusive licence agreement with the Japanese pharmaceutical firm Astellas last October to develop the therapy. It is now recruiting patients for its clinical trial in the UK, as well as the US, Poland, Spain, Sweden and the Netherlands. The infusion was administered in Warsaw in March 2024 in one of six patients who have had the treatment so far, in Poland and the US. All patients will be followed for up to five years as part of the trial. AviadoBio expects to publish the first data next year. Three years ago, Jessica Crawford, from Beverley in East Yorkshire, lost her mother, Julia, to FTD, caused by mutations of another gene, C9orf72. In 2014, when Julia was 58, her behaviour changed; the family suspected depression. Previously very sociable, she stopped going out and started playing games such as Candy Crush or watching TV shows 'over and over', her daughter recounts. Her mother initially did not want to see a doctor, and was only diagnosed with FTD in February 2019. By this time she was so confused she once put raw chicken in a sandwich. 'Getting the diagnosis wasn't easy because FTD wasn't well known; my mum was acing in the memory tests,' Jessica says. Julia became increasingly confused and lost the ability to speak, and then to communicate at all. Jessica became her full-time carer in 2020, but her mother deteriorated so much that she had to enter a care home in late 2021, and died the following year. Jessica, 33, found out she also carries the gene mutation, and with her husband decided to conceive through IVF with a pre-implantation genetic diagnosis. When their five embryos were screened, four had the gene mutation, and the fifth resulted in the birth of their son. The couple donated their other four embryos to science and she takes part in GENFI – a long-running UK-led global study of families with FTD across 40 sites. AviadoBio itself was born out of the research done at King's by Shaw, a neurologist who has focused on FTD and amyotrophic lateral sclerosis (ALS) for more than three decades, and Dr Youn Bok Lee and Dr Do Young Lee from the UK Dementia Research Institute's centre based at King's. ALS, the most common form of motor neurone disease, has also been linked to mutations of the GRN gene and leads to muscle weakness, paralysis and eventually death. Shaw acts as the company's chief scientific and clinical adviser, and while the Lees are no longer involved in the firm's research, all three remain shareholders. David Cooper, AviadoBio's chief medical officer, says: 'It was something that hit me when I first joined the company, [when] you look at the MRI scans of patients with a GRN mutation, the frontal and temporal parts of their brain are just melting away … So we really need earlier treatment, an earlier diagnosis and a more organised healthcare approach to deal with it.' AviadoBio's lead product, AVB-101, is infused directly into the brain by a neurosurgeon using a cannula as thin as a strand of angel hair pasta, during a 90-minute procedure guided by MRI. It delivers a functional copy of the progranulin gene to restore appropriate levels of the protein to affected areas of the brain. It is a one-off treatment, and no immunosuppressant drugs are needed afterwards. 'The patients who have FTD are born with almost half of the progranulin levels that you and I might have,' says the chief executive, Lisa Deschamps. 'Our goal in the study is to supplement the GRN gene and restore as much progranulin in these individuals as possible to normal levels to reduce the neurodegeneration effect.' Other medications in development around the world include two gene therapies, from Philadelphia-based Passage Bio and Eli Lilly-owned Prevail Therapeutics, but they do not target the thalamus, the 'relay station' in the brain. Passage Bio's therapies are delivered directly to the cerebrospinal fluid in a single treatment. Denmark's Vesper Bio has developed an oral capsule, designed to act on the GRN gene, that is being trialled at University College London hospital. AviadoBio, whose investors include Johnson & Johnson's innovation arm and the UK not-for-profit LifeArc Ventures, is part of a growing life science cluster in Canary Wharf. At its labs, scientists – assisted by robotics – research how to target a particular gene. 'The UK has real strengths in this area,' says Rowe, pointing to the international GENFI study, run since 2011 by Prof Jonathan Rohrer, a neurologist from UCL Queen Square Institute of Neurology who also sits on AviadoBio's scientific advisory board. 'It's a real win for the UK.'
Newsweek
9 hours ago
- Newsweek
Map Reveals Where To Look for Aurora Over US Tonight As Storm Hits Earth
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Northern Lights could be visible across parts of the U.S. this Friday. The National Oceanic and Atmospheric Administration (NOAA), has issued a geomagnetic storm warning. Current projections suggest a G2 level storm, moderate in strength, with the potential to pull the northern lights as far south as Idaho and New York. The northern lights have forecast with a "Kp index "rating of 4 which, based on the standard scale of 0 to 9, suggests stargazers can expect "more auroral activity" that has the potential to be "quite pleasing to look at." The agency's forecasts suggested that the phenomena may appear directly over Alaska, Idaho, Maine, Michigan, Minnesota, Montana, North Dakota, South Dakota, Washington and Wisconsin. The northern lights are expected to be just as visible on Saturday night with the NOAA forecasting a "coronal hole high speed stream", bringing with it a Kp index of 4 across the same 10 states. A map showing an Aurora viewline for the night of June 13. A map showing an Aurora viewline for the night of June 13. SWPC NOAA How To See the Aurora To ensure you have the best chance of spotting the northern lights Friday and Saturday night NOAA recommends looking skyward either just after sunset, or just before sunrise. It is not visible during daylight hours. According to NOAA, the lights are at their brightest from about 10 p.m. to 2 a.m. local time. "The aurora does not need to be directly overhead but can be observed from as much as a 1,000 km [621 miles] away when the aurora is bright and if conditions are right," the agency explains on its website. The northern lights are easiest to spot in clear weather and in places where the skies are darker—away from sources of light pollution like cities. Stargazers are also advised to find a high vantage point and travel as far north as possible. Pictured: Stock image of the Aurora Borealis over Fairbanks, Alaska. Pictured: Stock image of the Aurora Borealis over Fairbanks, Alaska. ElizabethWhat Causes the Northern Lights? The northern (and southern) lights form when particles from the solar wind excite atoms in the Earth's upper atmosphere, causing them to glow. Appearing as curtains of light that trace along the geomagnetic field lines, the aurorae vary in color depending on the particular species of atoms being excited. As Earth's atmospheric composition is dominated by oxygen and nitrogen, aurorae tend to give off a green hue (from the former) or a blue–pink–purple light (from the latter.) The geomagnetic storms forecast for this week are the result of a corotating interaction region—a transition zone produced by the meeting of fast and slow-moving streams in the solar wind. The interaction of the two streams creates a compression region in the solar wind that appears to rotate in step with the sun, hence the name. The fast stream causing this week's corotating interaction region is being powered by a massive hole in the southern hemisphere of the sun's corona, which is presently facing toward Earth. Do you have a tip on a science story that Newsweek should be covering? Do you have a question about the northern lights? Let us know via science@
